Sec Form 4 Filing - Meckler Jeffrey A @ Indaptus Therapeutics, Inc. - 2026-02-11

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Meckler Jeffrey A 2. Issuer Name and Ticker or Trading Symbol Indaptus Therapeutics, Inc. [ INDP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Co-Chief Executive Officer (Last) (First) (Middle) C/O INDAPTUS THERAPEUTICS, INC, 3 COLUMBUS CIRCLE, 15TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 02/11/2026 (Street) NEW YORK, NY10019 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants (right to buy) $ 47.6 02/11/2026 D 3,033 08/08/2024 08/08/2029 Common Stock 3,033 ( 1 ) 0 D Warrants (right to buy) $ 1.75 02/11/2026 A 3,033 02/11/2026 08/08/2029 Common Stock 3,033 ( 1 ) 3,033 D Warrants (right to buy) $ 29.4 02/11/2026 D 1,519 11/25/2024 11/25/2029 Common Stock 1,519 ( 1 ) 0 D Warrants (right to buy) $ 1.75 02/11/2026 A 1,519 02/11/2026 11/25/2029 Common Stock 1,519 ( 1 ) 1,519 D Warrants (right to buy) $ 8.3 02/11/2026 D 12,136 07/27/2025 07/27/2030 Common Stock 12,136 ( 1 ) 0 D Warrants (right to buy) $ 1.75 02/11/2026 A 12,136 02/11/2026 07/27/2030 Common Stock 12,136 ( 1 ) 12,136 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Meckler Jeffrey A C/O INDAPTUS THERAPEUTICS, INC 3 COLUMBUS CIRCLE, 15TH FLOOR NEW YORK, NY10019 X Co-Chief Executive Officer Signatures /s/ Jeffrey Meckler 02/13/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Effective February 11, 2026, the Board of Directors of the Company approved a unilateral reduction in the per share exercise price of the warrants to $1.75. All of the other terms of the warrants remained unchanged.

Remarks: On June 26, 2025, the Company effected a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.